Advanced Biomarkers: Beyond Amyloid and Tau: Emerging Non-Traditional Biomarkers for Alzheimer’s Diagnosis and Progression DOI

Meher Rijwana Afrin,

P. Upadhyaya,

A. Hashim

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102736 - 102736

Published: March 1, 2025

Language: Английский

Reevaluating the sleep-dementia link: Methodological gaps and future directions DOI Creative Commons
Julián Benito‐León,

Carla María Benito-Rodríguez

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown, P. 100085 - 100085

Published: Feb. 1, 2025

Language: Английский

Citations

0
Blood-Based β-Amyloid and Phosphorylated Tau (p-Tau) Biomarkers in Alzheimer’s Disease: A Systematic Review of Their Diagnostic Potential DOI Open Access

Meghana Dasari,

Joel Abraham Kurian,

Sumanth Gundraju

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuropathological features such as amyloid-β (Aβ) plaques phosphorylated tau (p-Tau) tangles. Blood-based biomarkers of Aβ p-Tau have emerged promising tools for early diagnosis, monitoring, risk stratification AD. This systematic review evaluates current evidence on the diagnostic utility blood in followed Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web Science studies published between 2011 2024. synthesizes findings from 33 peer-reviewed to evaluate prognostic these biomarkers. Results demonstrate that levels strongly correlate with cerebrospinal fluid (CSF) neuroimaging measures AD pathology. Among analyzed, (including p-Tau181 p-Tau217) consistently exhibited superior accuracy, particularly distinguishing mild impairment (MCI) cognitively normal individuals. The combination further improved precision, supporting their complementary roles pathology detection. Despite findings, significant heterogeneity among underscores need assay standardization, validation diverse populations, longitudinal research establish clinical utility. study concludes blood-based represent advance diagnostics, offering non-invasive, cost-effective, scalable solutions detection therapeutic monitoring.

Language: Английский

Citations

0
Utilizing Nanomaterials in Microfluidic Devices for Disease Detection and Treatment DOI Creative Commons
Zhenyu Tian, Yatian Fu, Zhaolong Dang

et al.

Nanomaterials, Journal Year: 2025, Volume and Issue: 15(6), P. 434 - 434

Published: March 12, 2025

Microfluidic technology has gained widespread application in the field of biomedical research due to its exceptional sensitivity and high specificity. Particularly when combined with nanomaterials, synergy between two significantly advanced fields such as precision medicine, drug delivery, disease detection, treatment. This article aims provide an overview latest achievements microfluidic nanomaterials detection It delves into applications detecting blood parameters, cardiovascular markers, neurological tumor markers. Special emphasis is placed on their roles treatment, including models vessels, blood–brain barrier, lung chips, tumors. The development emerging medical technologies, particularly skin interactive devices imaging, also introduced. Additionally, challenges future prospects current clinical are discussed. In summary, play indispensable role With continuous advancement technology, will become even more profound extensive.

Language: Английский

Citations

0
Advanced Biomarkers: Beyond Amyloid and Tau: Emerging Non-Traditional Biomarkers for Alzheimer’s Diagnosis and Progression DOI

Meher Rijwana Afrin,

P. Upadhyaya,

A. Hashim

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102736 - 102736

Published: March 1, 2025

Language: Английский

Citations

0